🟢 Summit Therapeutics is trading 16.3% up in after-hours trading with no confirmed new catalyst

Summit Therapeutics is trading 16.3% higher after hours at $18.00, with no new company announcement after the close confirmed in sources reviewed.

• This compares with the September 28 regular-session close of $15.48.
• The latest listed company release was September 22, about a Phase III trial presentation at ESMO 2026.
• Possible AstraZeneca licensing discussions were reported September 25, with no guaranteed deal; broader indexes were lower September 28.